News
XBIO
2.780
+0.36%
0.010
Weekly Report: what happened at XBIO last week (0609-0613)?
Weekly Report · 5d ago
Xenetic Biosciences Reports Improved Q1 2025 Results
TipRanks · 06/11 03:50
Weekly Report: what happened at XBIO last week (0602-0606)?
Weekly Report · 06/09 11:56
Weekly Report: what happened at XBIO last week (0526-0530)?
Weekly Report · 06/02 12:07
Weekly Report: what happened at XBIO last week (0519-0523)?
Weekly Report · 05/26 12:06
Weekly Report: what happened at XBIO last week (0512-0516)?
Weekly Report · 05/19 11:54
Xenetic Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 05/14 18:15
Xenetic reports Q1 EPS (59c) vs. (78c) last year
TipRanks · 05/14 12:40
Xenetic Biosciences reports Q1 results
Seeking Alpha · 05/14 12:21
XENETIC BIOSCIENCES Q1 NET INCOME USD -900 THOUSAND
Reuters · 05/14 12:05
H.C. Wainwright Sticks to Its Hold Rating for Xenetic Biosciences (XBIO)
TipRanks · 05/14 10:42
Xenetic Biosciences Q1 EPS $(0.59) Beats $(0.72) Estimate, Sales $593.26K Miss $670.00K Estimate
Benzinga · 05/13 21:58
Xenetic Biosciences: Q1 Earnings Snapshot
Barchart · 05/13 16:09
Weekly Report: what happened at XBIO last week (0505-0509)?
Weekly Report · 05/12 11:55
Weekly Report: what happened at XBIO last week (0428-0502)?
Weekly Report · 05/05 11:58
Weekly Report: what happened at XBIO last week (0421-0425)?
Weekly Report · 04/28 12:10
USANA Health Sciences (USNA) Q1 Earnings and Revenues Surpass Estimates
NASDAQ · 04/22 21:15
Weekly Report: what happened at XBIO last week (0414-0418)?
Weekly Report · 04/21 12:09
Weekly Report: what happened at XBIO last week (0407-0411)?
Weekly Report · 04/14 11:55
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral
Benzinga · 04/09 16:46
More
Webull provides a variety of real-time XBIO stock news. You can receive the latest news about Xenetic Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About XBIO
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The Company's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. It is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.